FNArena Windows

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

A new specialty female oral contraceptive will grace the portfolio of Mayne Pharma, providing a substantial growth opportunity in the medium-long term.

Oct 03 2019

Two Ways To Play The Pain Medication Game

The New Criterion’s Tim Boreham notes massive legal settlements in the US have highlighted the scourge of opioid abuse, but Australian producer Palla Pharma is confident the drug class will remain the world’s foremost pain medication.

Oct 03 2019

1AD $0.13


$0.29 $0.11



CSL $250.97


$258.65 $173.00 38.5



MYX $0.59


$1.25 $0.43 26.7



PAR $2.64


$3.26 $0.00



PNV $2.40


$2.66 $0.51 -800.0



RNO $0.27 0.00% $0.41 $0.14



SPL $1.13 0.00% $1.66 $0.87



Previous Stories
CSL: Positive Signs

Sep 19 2019

The Chartist reports CSL appears to be setting up for another push higher so it’s one to watch.

CSL Retains Superior Position In Plasma

Aug 16 2019

A superior position in plasma collections in the US has delivered benefits to CSL in FY19 and, while competitors are gearing up, brokers believe the outlook for FY20 remains firm.

RESEARCH: Anatara Lifesciences’¬†Potential Remains

Jul 17 2019

Pitt Street Research has amended its modeling for Anatara Lifesciences, believing the loss of partner Zoetis is only a temporary set-back.

RESEARCH: Invion, Helping Cancer To See The Light

May 23 2019

Pitt Street Research has initiated coverage of Invion, a company hoping to develop a new Photodynamic Therapy (PDT) for the treatment of cancer.

Mayne Pharma Reviewing Generics

May 15 2019

Increased competition in generic drugs has caused a significant deterioration in Mayne Pharma earnings and the company is reviewing the carrying value of these assets.

RESEARCH: Interview With CEO Anatara Lifesciences

Apr 17 2019

Stuart Roberts of Pitt Street Research talks to Steve Lydeamore, CEO of Anatara Lifesciences.

Treasure Chest: Time To Buy Mayne Pharma?

Apr 16 2019

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. After a long period with a negative or neutral position on Mayne Pharma, Wilsons has decided now is the time to buy.

RESEARCH: Anatara Lifesciences’¬†Zoetis Deal A Company Maker

Mar 15 2019

Pitt Street Research has initiated coverage of Anatara Lifesciences with a bullish view on the recent licensing agreement with Zoetis.

RESEARCH: Neuren Keeps Rest-of-World Rights For Trofinetide

Mar 07 2019

Pitt Street Research sees a case for re-rating as Neuren keeps Rest-of-World rights for Trofinetide.

RESEARCH: New Standard in Pain Assessment

Dec 12 2018

Pitt Street Research has initiated coverage of PainChek.